Text Size

Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Bagcilar Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT01735331
First received: November 26, 2012
Last updated: NA
Last verified: November 2012
History: No changes posted
  Purpose

The aim of this study is determine vascular endothelial growth factor levels at hysteroscopic endometrial biopsies which taken from patients who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels will be measured by immunohistochemical staining methods due to office hysteroscopic endometrial biopsy after the menstruation at follicular phase of menstrual cycle.


Condition
Recurrent Pregnancy Loss Without Current Pregnancy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss

Further study details as provided by Bagcilar Training and Research Hospital:

Primary Outcome Measures:
  • The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: November 2012
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
VEGF level
VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
control group
Patients with Abnormal Uterine Bleeding

Detailed Description:

This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.

Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The patients with Recurrent Pregnancy Loss

Criteria

Inclusion Criteria:

  • Patients with Recurrent Pregnancy Loss who accept to join the study.

Exclusion Criteria:

  • Patients whose age of <18 and >45
  • Patients with have any pregnancy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01735331

Locations
Turkey
Bagcilar Training and Research Hospital
Istanbul, Turkey
Sponsors and Collaborators
Bagcilar Training and Research Hospital
Investigators
Principal Investigator: TANER A. USTA, M.D. Bagcilar Training and Research Hospital,Istanbul,Turkey.
  More Information

No publications provided

Responsible Party: Bagcilar Training and Research Hospital
ClinicalTrials.gov Identifier: NCT01735331     History of Changes
Other Study ID Numbers: BEHGynObs-3
Study First Received: November 26, 2012
Last Updated: November 26, 2012
Health Authority: Turkey: Ministry of Health

Keywords provided by Bagcilar Training and Research Hospital:
Vascular endothelial growth factor, Recurrent Pregnancy Loss

Additional relevant MeSH terms:
Mitogens
Endothelial Growth Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
 Pharmacologic Actions
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013